The FDA has granted "breakthrough" status to GlaxoSmithKline's (GSK) Promacta/Revolade (eltrombopag) drug for the treatment of cytopenias in patients with severe aplastic anaemia (SAA) who have had insufficient response to immunosuppressive therapy (IST).
"SAA is a rare disorder in which the bone marrow fails to make enough new blood cells," GSK says. "Of those patients unresponsive to initial IST, approximately 40% die from infection or bleeding within five years of their diagnosis." Cytopenia is a fall in the number of blood cells. (PR)
Meanwhile, GSK is set to announce plans to start late-stage trials on ten drugs over the next two years, The Daily Telegraph reports. The testing will include treatments in GSK's key areas of cancer and respiratory disease.